2026-04-14T03:09:24Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/84932025-10-24T10:19:24Zcom_2072_378070com_2072_378040col_2072_378092

Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry Bryce, Jillian Ali, Salma R. van den Akker, Erica Clemente Leon, Maria Lawrence, Neil Bacila, Irina Dawson, Jeremy Institut Català de la Salut [Lawrence N] Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK. [Bacila I] Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. [Dawson J] Institute of Work Psychology, Management School, University of Sheffield, Sheffield, UK. School of Health and Related Research, University of Sheffield, Sheffield, UK. [Bryce J] Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK. Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK. [Ali SR] Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK. Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK. Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK. [van den Akker ELT] Department of Pediatric Endocrinology, Sophia Children's Hospital, Erasmus Medical Centre, Rotterdam, the Netherlands. [Clemente M] Servei d’Endocrinologia Pediàtrica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBER de Enfermedades Raras (CIBERER) ISCIII, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Hiperplàsia - Tractament Malalties congènites - Tractament Hidrocortisona - Ús terapèutic DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Adrenal Hyperplasia, Congenital Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Polycyclic Compounds::Fused-Ring Compounds::Steroids::Pregnanes::Pregnenes::Pregnenediones::Hydrocortisone Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::hiperplasia suprarrenal congénita Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides::pregnanos::pregnenos::pregnenodionas::hidrocortisona Otros calificadores::Otros calificadores::/uso terapéutico Biomarkers; Congenital adrenal hyperplasia; Hydrocortisone Biomarcadores; Hiperplasia suprarrenal congénita; Hidrocortisona Biomarcadors; Hiperplàsia suprarenal congènita; Hidrocortisona Objective Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4). Design Retrospective cohort study using real-world data to evaluate 17OHP and D4 in relation to hydrocortisone (HC) dose in CAH patients treated in 14 countries. Patients Pseudonymized data from children with 21-hydroxylase deficiency (21OHD) recorded in the International CAH Registry. Measurements Assessments between January 2000 and October 2020 in patients prescribed HC were reviewed to summarise biomarkers 17OHP and D4 and HC dose. Longitudinal assessment of measures was carried out using linear mixed-effects models (LMEM). Results Cohort of 345 patients, 52.2% female, median age 4.3 years (interquartile range: 3.1–9.2) were taking a median 11.3 mg/m2/day (8.6–14.4) of HC. Median 17OHP was 35.7 nmol/l (3.0–104.0). Median D4 under 12 years was 0 nmol/L (0–2.0) and above 12 years was 10.5 nmol/L (3.9–21.0). There were significant differences in biomarker values between centres (p < 0.05). Correlation between D4 and 17OHP was good in multiple regression with age (p < 0.001, R2 = 0.29). In longitudinal assessment, 17OHP levels did not change with age, whereas D4 levels increased with age (p < 0.001, R2 = 0.08). Neither biomarker varied directly with dose or weight (p > 0.05). Multivariate LMEM showed HC dose decreasing by 1.0 mg/m2/day for every 1 point increase in weight standard deviation score. Discussion Registry data show large variability in 17OHP and D4 between centres. 17OHP correlates with D4 well when accounting for age. Prescribed HC dose per body surface area decreased with weight gain. This project has received support from the I-CAH Registry project that receives unrestricted education grants from Diurnal Ltd and Neurocrine Biosciences. The initial development of the Registry was supported by the Medical Research Council (G1100236), the Seventh European Union Framework Program (201444) and the European Society for Paediatric Endocrinology Research Unit. NRL is funded by an NIHR Academic Clinical Fellowship. SRA is supported by the Gardiner Lectureship at the University of Glasgow. This study was funded by an award to NPK from the DFG, German Research Foundation (KR3363/3-1). 2022-11-17T08:17:45Z 2022-11-17T08:17:45Z 2022-11 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Lawrence N, Bacila I, Dawson J, Bryce J, Ali SR, van den Akker ELT, et al. Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry. Clin Endocrinol. 2022 Nov;97(5):551–61. 1365-2265 https://hdl.handle.net/11351/8493 10.1111/cen.14796 35781728 000822943200001 http://hdl.handle.net/11351/8493 eng Clinical Endocrinology;97(5) https://doi.org/10.1111/cen.14796 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Wiley Scientia